Search Videos and More
News
UT Southwestern: A global leader in robotic pancreas surgery
Traditionally performed through a large incision, at UT Southwestern our pancreatic cancer surgeons have specialized in robotic-assisted Whipple surgery, a more precise approach through smaller incisions that has been proven to benefit patients with faster recovery times, less pain, less use of pain medication, and prompter return to work. It has also been shown to have comparable cancer treatment results with lower rates of complications and transfusions than the open surgery.
News
Response to Hormone Therapy Predicts Radiation Resistance in ER+ Breast Cancer
How estrogen receptor-positive (ER+) breast cancer responds to hormone therapy may hold keys to understanding how it will respond to radiation therapy, and an experimental drug that increases the effectiveness of hormone therapy also overcomes radiation resistance in breast cancer, a study by UT Southwestern Medical Center researchers shows.
Video
Robotic Nipple-Sparing Mastectomy at UT Southwestern
When Renee Mallonee found out she was BRCA2 positive and her lifetime risk of breast cancer was high, she took this news very seriously. After 15 years of screenings and tests every 6 months, she turned to UT Southwestern for a prophylactic mastectomy.
News
Liver cancer treatment costly for Medicare patients, UT Southwestern study finds
Hepatocellular carcinoma (HCC), the most common type of liver cancer, can place a significant financial burden on patients, according to an analysis led by a researcher at UT Southwestern Medical Center.
News
Using Artificial Intelligence to Personalize Lung Cancer Treatment
UT Southwestern research combining artificial intelligence with traditional pathology analysis holds potential for quickly creating a personalized attack plan for cancer patients when speed is essential: as non-small cell lung cancers spread. This approach identified lung cancers that are most likely to respond to one common treatment versus those that might benefit from a different approach.
News
New Drug Combination Offers Hope for Improved Treatment of Cervical Cancer
A new combination of drugs slowed the growth of cancer cells by an unexpected mechanism that may one day lead to improved treatment of cervical cancer, a UT Southwestern-led study published in Molecular Cancer Research suggests.
News
Preoperative Partial Breast Irradiation for Early-Stage Breast Cancer
The current standard of care for early-stage breast cancer is to first surgically remove the tumor, then deliver postoperative radiation therapy.
News
The PROMISE of a Better Pediatric Radiation Experience
Treating the pediatric radiation oncology population has historically been difficult. Because it is imperative to have patients stay still during radiation treatment, general anesthesia is commonly used to facilitate radiation treatments in children, with most children age 7 and under receiving general anesthesia.
News
UTSW’s adaptive therapy provides a personalized care plan to treat each individual’s cancer
In December 2021, Mr. Metcalf noticed a lump on his neck. He thought it was the result of something he had done days prior and decided to wait to see if it would disappear. The lump wasn’t painful, and he even forgot about it. However, once January came around and it remained the same size, he knew it was a serious issue that needed to be addressed.
News
UTSW Clinical Trial Sets Stage for New Paradigm in Kidney Cancer Treatment
Kidney cancer encompasses a wide spectrum and can present with extensive metastases or just a handful. However, today all patients are treated the same. They all receive medication.
News
Cell Competition May Explain Cancer Relapses, Research Suggests
A normal process called cell competition, in which healthy tissues eliminate unhealthy cells, could be responsible for cancer relapses in patients months or years after they were declared cancer-free, a new study by UT Southwestern researchers suggests.
News
Drug Shows Promise in Overcoming Endocrine Therapy Resistance in Breast Cancer
For patients with estrogen receptor (ER)-positive breast cancer, development of the so-called Y537S mutation signals that their disease has taken an aggressive course and may become resistant to endocrine therapy. Now a preclinical study, led by researchers at UT Southwestern Medical Center, suggests that a class of new drugs already in clinical trials might work especially well in breast cancer patients who have acquired this mutation.